Melatonin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Melatonin: From Insomnia to Migraine with Brainstem Aura
One-Sentence Summary
Melatonin is a sleep-regulating hormone, originally used to treat insomnia and sleep-initiation and sleep-maintenance disorders. The TxGNN model predicts it may be useful for migraine with brainstem aura. However, there are 0 clinical trials for this specific subtype and only 19 publications (mostly reviews and observational studies), so this is an early-stage hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Insomnia; sleep initiation and maintenance disorders (the Singapore licence text is blank, so this comes from the knowledge graph) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 87.90% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Pharmacology records show that melatonin acts on the MT1 and MT2 melatonin receptors and also has recorded activity at the 5-HT2B serotonin receptor. Through these receptors it regulates circadian rhythm and sleep timing.
Migraine and sleep are closely linked. Both poor sleep and excess sleep can trigger attacks. Several studies found lower nocturnal melatonin excretion in people with migraine. Melatonin also has antioxidant and anti-inflammatory effects and may modulate serotonergic and pain pathways. This gives a plausible mechanistic bridge from insomnia to migraine.
There are important limits:
- No trial or study targets the brainstem aura subtype. The support is extrapolated from general migraine research.
- Mechanistic evidence is mixed. A study in children and adolescents with episodic migraine found that urinary melatonin metabolite levels were not a useful biomarker for predicting attacks.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine with brainstem aura.
For context, the broader indication "migraine disorder" does have registered trials, including a completed Phase 3 trial comparing melatonin, amitriptyline and placebo (NCT01357031, n=192). Those trials do not directly test the brainstem aura subtype.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27165014 | 2016 | RCT (general migraine) | J Neurol Neurosurg Psychiatry | Randomised comparison of melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention |
| 24909684 | 2015 | Clinical study (pediatric) | Curr Drug Saf | Safety and efficacy of melatonin for migraine prophylaxis in children |
| 38166859 | 2024 | RCT (related agent) | BMC Neurol | Agomelatine, a melatonergic agent, for headache severity and frequency in episodic migraine without aura |
| 18810607 | 2008 | Open-label trial | Neurol Sci | 3-month open-label melatonin 3 mg in 22 children with migraine or tension-type headache |
| 31054199 | 2019 | Cohort (biomarker) | Headache | Evening urinary melatonin metabolite did not predict next-day migraine in children and adolescents |
| 7641249 | 1995 | Observational | Cephalalgia | Lower nocturnal melatonin excretion in women with menstrual migraine without aura |
| 7954740 | 1994 | Observational | Cephalalgia | Decreased urinary melatonin across the ovarian cycle in migraine without aura, suggesting impaired pineal function |
| 28194570 | 2017 | Review | J Headache Pain | Genetic and biochemical changes of the serotonergic system in migraine |
| 30906963 | 2019 | Review | Neurol Sci | Migraine, including with aura, is intrinsically related to sleep; sleep disorders and migraine form a vicious cycle |
| 24437268 | 2013 | Review | Nihon Rinsho | Circadian rhythm in primary headache; seasonal variation in attack frequency in migraine with aura |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13954P | CIRCADIN™ Prolonged Release Tablets 2 mg | Tablet, extended release (oral) | — (no indication text on record) |
Safety Considerations
- Contraindications (knowledge-graph associations, not label text): The knowledge graph links melatonin to caution in the following conditions. Verify them against the package insert.
- Liver and kidney disease, including liver failure
- Autoimmune disease, including systemic lupus erythematosus, psoriasis and sarcoidosis
- Psychiatric conditions: anxiety, dysthymic disorder, schizophrenia and substance abuse/dependence
- Calcium and phosphorus disorders, including hypercalcemia, nephrocalcinosis and kidney stones
- Others: gallbladder disease, constipation, acute urate nephropathy, paracetamol poisoning, digitalis poisoning and eosinophilia-myalgia syndrome
- Drug Interactions: 18 drug-drug interactions were recorded, mostly from DDInter.
- Moderate: warfarin, deferasirox, alpelisib, anagrelide, lorlatinib, olaparib, osimertinib, rucaparib, teriflunomide, vemurafenib and ifosfamide.
- Minor: cimetidine, caffeine, obeticholic acid, osilodrostat, ethinylestradiol and diethylstilbestrol.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (87.90%) and the biological link between melatonin, circadian rhythm and migraine is plausible. However, no trial and no direct clinical evidence exists for the brainstem aura subtype. The supporting studies are reviews, observational work and general-migraine studies, with mixed pediatric results. The related broader indication, migraine disorder, has stronger evidence and would be the more practical starting point.
To proceed, the following is needed:
- Mechanism-of-action data for melatonin from DrugBank
- The Singapore package insert, to confirm warnings, contraindications and approved indication text
- Evidence that the effect of melatonin in general migraine applies to the brainstem aura subtype, or a pilot study in that population
- A review of the knowledge-graph contraindications and the moderate drug interactions against the label before any use beyond the current indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.